TITLE:
Study of Motexafin Gadolinium for the Treatment of Non-Hodgkin's Lymphoma

CONDITION:
Lymphoma

INTERVENTION:
Motexafin gadolinium

SUMMARY:

      The primary purpose of this study is to find out if motexafin gadolinium may be an effective
      treatment for patients with non-Hodgkin's lymphoma (NHL). Secondly, the safety and side
      effects of motexafin gadolinium will be evaluated.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria:

          -   18 years old

          -  Refractory or relapsed indolent NHL. Eligible WHO histologies include follicular NHL
             (Grades 1, 2, and 3); marginal zone nodal; marginal zone splenic; and
             mucosa-associated lymphoid tissue (MALT) types

          -  Failed  1 previous regimens, one of which must have contained rituximab as either a
             single agent or in combination with chemotherapy

          -  ECOG performance status score either 0 or 1

          -  Willing and able to provide written informed consent

        Exclusion Criteria:

        Laboratory values of:

          -  Platelet count < 50,000/L

          -  AST or ALT > 2 x the upper limit of normal (ULN)

          -  Total bilirubin > 2 x ULN

          -  Creatinine > 2.0 mg/dL

        and

          -  Greater than three prior regimens (where a regimen is defined as a treatment for NHL
             given after disease progression)

          -  Uncontrolled hypertension

          -  Known history of porphyria, G6PD deficiency, HIV
      
